Tamoxifen (TAM), a nonsteroidal antiestrogen drug, is the most-prescribed selective estrogen receptor modulator2 used to treat luminal A breast cancer patients, and it decreases mortality rate to 31%3. Here, ESR1 is linked to breast carcinoma.